Detalhe da pesquisa
1.
Circulating CD8 lymphocytes predict response to atezolizumab-bevacizumab in hepatocellular carcinoma.
Eur J Immunol
; 54(2): e2350637, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37990855
2.
Genetic, Immunological, Dietary, Gut Microbiota, and Environmental Determinants of Osteoporosis in the Course of Celiac Disease: Which Factor Plays the First Violin in This Orchestra?
Calcif Tissue Int
; 114(2): 98-109, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38049681
3.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517286
4.
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
J Hepatol
; 78(1): 133-141, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36341767
5.
COVID-19: Has the Liver Been Spared?
Int J Mol Sci
; 24(2)2023 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36674607
6.
Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second-line clinical trials.
Liver Int
; 42(2): 458-467, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34826193
7.
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster.
BMC Med Genet
; 21(1): 225, 2020 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33208122
8.
Telomerase reactivation is associated with hepatobiliary and pancreatic cancers.
Hepatobiliary Pancreat Dis Int
; 19(5): 420-428, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386990
9.
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.
J Hepatol
; 71(6): 1175-1183, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31449860
10.
Have We Found the "Holy Grail" That May Predict Response to Immunotherapy in Hepatocellular Carcinoma?
Gastroenterology
; 164(1): 15-18, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36334819
11.
New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm.
Gut
; 67(9): 1674-1682, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29437912
12.
From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma.
Histopathology
; 72(3): 414-422, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881044
13.
Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma.
Liver Int
; 38(2): 278-284, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28792650
14.
Metabolic disorders across hepatocellular carcinoma in Italy.
Liver Int
; 38(11): 2028-2039, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29745475
15.
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
Eur Radiol
; 28(9): 3611-3620, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29633000
16.
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study.
Future Oncol
; 14(29): 3049-3058, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30091371
17.
Microbiota, NASH, HCC and the potential role of probiotics.
Carcinogenesis
; 38(3): 231-240, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28426878
18.
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.
J Hepatol
; 67(1): 173-183, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28323121
19.
Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
Future Oncol
; 13(21): 1893-1905, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28693355
20.
A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease.
Int J Mol Sci
; 18(6)2017 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28587063